药捷安康-B(02617.HK)公布招股结果,香港公开发售接获3,419.87倍认购,一手(500股)中签率0.8%。国际发售录得0.97倍认购。经重新分配,公开发售股份已增加至305.7万股,占发售总数20%。股份预期周一(23日)挂牌。生物制药公司药捷安康是次全球发售1,528.1万股,公开发售占10%。招股价13.15元,集资净额1.61亿元。五名基石投资者江北医药、康方生物(09926....
Source Link药捷安康-B(02617.HK)公布招股结果,香港公开发售接获3,419.87倍认购,一手(500股)中签率0.8%。国际发售录得0.97倍认购。经重新分配,公开发售股份已增加至305.7万股,占发售总数20%。股份预期周一(23日)挂牌。生物制药公司药捷安康是次全球发售1,528.1万股,公开发售占10%。招股价13.15元,集资净额1.61亿元。五名基石投资者江北医药、康方生物(09926....
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.